Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

The efficacy and safety of monoclonal antibody treatments against COVID-19: A systematic review and meta-analysis of randomized clinical trials

View ORCID ProfileIfan Ali Wafa, Nando Reza Pratama, David Setyo Budi, View ORCID ProfileHenry Sutanto, View ORCID ProfileAlfian Nur Rosyid, Citrawati Dyah Kencono Wungu
doi: https://doi.org/10.1101/2021.06.04.21258343
Ifan Ali Wafa
aFaculty of Medicine, Universitas Airlangga, Indonesia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ifan Ali Wafa
Nando Reza Pratama
aFaculty of Medicine, Universitas Airlangga, Indonesia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Setyo Budi
aFaculty of Medicine, Universitas Airlangga, Indonesia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Henry Sutanto
bDepartment of Cardiology, CARIM School for Cardiovascular Diseases, Maastricht University, The Netherlands
cDepartment of Physiology and Biophysics, State University of New York (SUNY) Downstate Health Sciences University, New York, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Henry Sutanto
Alfian Nur Rosyid
dDepartment of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Airlangga, Indonesia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Alfian Nur Rosyid
Citrawati Dyah Kencono Wungu
eDepartment of Physiology and Medical Biochemistry, Faculty of Medicine, Universitas Airlangga, Indonesia
fInstitute of Tropical Disease, Universitas Airlangga, Indonesia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: citrawati.dyah@fk.unair.ac.id
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Objectives The use of monoclonal antibody for COVID-19 showed conflicting results in prior studies and its efficacy remains unclear. We aimed to comprehensively determine the efficacy and safety profile of monoclonal antibodies in COVID-19 patients.

Methods Sixteen RCTs were analyzed using RevMan 5.4 to measure the pooled estimates of risk ratios (RRs) and standardized mean differences (SMDs) with 95% CIs.

Results The pooled effect of monoclonal antibodies demonstrated mortality risk reduction (RR=0.89 (95%CI 0.82-0.96), I2=13%, fixed-effect). Individually, tocilizumab reduced mortality risk in severe to critical disease (RR=0.90 (95%CI 0.83-0.97), I2=12%, fixed-effect)) and lowered mechanical ventilation requirements (RR=0.76 (95%CI 0.62-0.94), I2=42%, random-effects). Moreover, it facilitated hospital discharge (RR=1.07 (95%CI 1.00-1.14), I2=60%, random-effects). Meanwhile, bamlanivimab-etesevimab and REGN-COV2 decrease viral load ((SMD=-0.33 (95%CI -0.59 to -0.08); (SMD=-3.39 (95%CI -3.82 to -2.97)). Interestingly, monoclonal antibodies did not improve hospital discharge at day 28-30 (RR=1.05 (95%CI 0.99–1.12), I2=71%, random-effects) and they displayed similar safety profile with placebo/standard therapy (RR=1.04 (95%CI 0.76-1.43), I2=54%, random-effects).

Conclusion Tocilizumab improved hospital discharge and reduced mortality as well as the need for mechanical ventilation, while bamlanivimab-etesevimab and REGN-COV2 reduced viral load in mild to moderate outpatients. In general, monoclonal antibodies are safe and should be considered in severe to critical COVID-19 patients.

Registration PROSPERO (CRD42021235112)

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

Not available

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Not available, as it is a meta-analysis

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Not available

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.
Back to top
PreviousNext
Posted June 07, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
The efficacy and safety of monoclonal antibody treatments against COVID-19: A systematic review and meta-analysis of randomized clinical trials
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
The efficacy and safety of monoclonal antibody treatments against COVID-19: A systematic review and meta-analysis of randomized clinical trials
Ifan Ali Wafa, Nando Reza Pratama, David Setyo Budi, Henry Sutanto, Alfian Nur Rosyid, Citrawati Dyah Kencono Wungu
medRxiv 2021.06.04.21258343; doi: https://doi.org/10.1101/2021.06.04.21258343
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
The efficacy and safety of monoclonal antibody treatments against COVID-19: A systematic review and meta-analysis of randomized clinical trials
Ifan Ali Wafa, Nando Reza Pratama, David Setyo Budi, Henry Sutanto, Alfian Nur Rosyid, Citrawati Dyah Kencono Wungu
medRxiv 2021.06.04.21258343; doi: https://doi.org/10.1101/2021.06.04.21258343

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (179)
  • Allergy and Immunology (434)
  • Anesthesia (99)
  • Cardiovascular Medicine (948)
  • Dentistry and Oral Medicine (178)
  • Dermatology (110)
  • Emergency Medicine (260)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (422)
  • Epidemiology (8987)
  • Forensic Medicine (4)
  • Gastroenterology (420)
  • Genetic and Genomic Medicine (1958)
  • Geriatric Medicine (190)
  • Health Economics (402)
  • Health Informatics (1329)
  • Health Policy (660)
  • Health Systems and Quality Improvement (519)
  • Hematology (212)
  • HIV/AIDS (420)
  • Infectious Diseases (except HIV/AIDS) (10808)
  • Intensive Care and Critical Care Medicine (575)
  • Medical Education (200)
  • Medical Ethics (54)
  • Nephrology (222)
  • Neurology (1830)
  • Nursing (110)
  • Nutrition (274)
  • Obstetrics and Gynecology (353)
  • Occupational and Environmental Health (470)
  • Oncology (999)
  • Ophthalmology (298)
  • Orthopedics (111)
  • Otolaryngology (182)
  • Pain Medicine (126)
  • Palliative Medicine (44)
  • Pathology (265)
  • Pediatrics (580)
  • Pharmacology and Therapeutics (276)
  • Primary Care Research (234)
  • Psychiatry and Clinical Psychology (1903)
  • Public and Global Health (4123)
  • Radiology and Imaging (676)
  • Rehabilitation Medicine and Physical Therapy (368)
  • Respiratory Medicine (549)
  • Rheumatology (225)
  • Sexual and Reproductive Health (191)
  • Sports Medicine (177)
  • Surgery (207)
  • Toxicology (39)
  • Transplantation (109)
  • Urology (81)